Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2019
At a glance
- Drugs BMS 986094 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms CARE-HepC
- 25 Apr 2018 Status changed from active, no longer recruiting to completed.
- 16 Apr 2018 Planned End Date changed from 1 May 2018 to 18 Apr 2018.
- 16 Apr 2018 Planned primary completion date changed from 1 Apr 2018 to 18 Apr 2018.